Professor Graham Jackson
| Progression free survival of myeloma patients who become IFE-negative correlates with the detection of residual monoclonal free light chain (FLC) by mass spectrometry | 2024 |
|
Professor Graham Jackson
| Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm | 2024 |
|
Dr Sarah Fordham
Dr Wei-Yu Lin
Dr Helen Blair
Dr Claire Elstob
Dr Hayden Bell
et al. | Biallelic TET2 mutations confer sensitivity to 5′-azacitidine in acute myeloid leukemia | 2023 |
|
Professor Graham Jackson
| Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma | 2023 |
|
Professor Graham Jackson
| Delayed diagnosis resulting in increased disease burden in multiple myeloma: the legacy of the COVID-19 pandemic | 2023 |
|
Professor Graham Jackson
| Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial | 2023 |
|
Professor Graham Jackson
| Optimizing the value of lenalidomide maintenance by extended genetic profiling: an analysis of 556 patients in the Myeloma XI trial | 2023 |
|
Professor Graham Jackson
| The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from ‘Myeloma XI’, a multicentre, open-label, randomised, phase III trial | 2023 |
|
Dr Wei-yu Lin
Dr Sarah Fordham
Dr Nicola Sunter
Dr Claire Elstob
Dr Yaobo Xu
et al. | Author Correction: Genome-wide association study identifies susceptibility loci for acute myeloid leukemia (Nature Communications, (2021), 12, 1, (6233), 10.1038/s41467-021-26551-x) | 2022 |
|
Professor Graham Jackson
| Clinical characteristics and outcomes of IgD myeloma: experience across UK national trials | 2022 |
|
Professor Graham Jackson
| Defining FiTNEss for treatment for multiple myeloma | 2022 |
|
Professor Graham Jackson
| Redefining nonmeasurable multiple myeloma using mass spectrometry | 2022 |
|
Professor Graham Jackson
| Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial | 2021 |
|
Professor Graham Jackson
| Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - A meta-analysis of 2,596 trial patients | 2021 |
|
Professor Graham Jackson
| Copy number evolution and its relationship with patient outcome—an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial | 2021 |
|
Professor Graham Jackson
Professor Marcus Kaiser
| Early relapse after high-dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high-risk disease in multiple myeloma | 2021 |
|
Dr Wei-Yu Lin
Dr Sarah Fordham
Dr Nicola Sunter
Dr Claire Elstob
Dr Yaobo Xu
et al. | Genome-wide association study identifies susceptibility loci for acute myeloid leukemia | 2021 |
|
Professor Graham Jackson
| Safety of lenalidomide for maintenance treatment of patients with multiple myeloma following autologous stem cell transplantation | 2021 |
|
Professor Graham Jackson
| BRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma | 2020 |
|
Professor Graham Jackson
| An enhanced genetic model of relapsed IGH-translocated multiple myeloma evolutionary dynamics | 2020 |
|
Dr Laura Jardine
Dr Urszula Cytlak-Chaudhuri
Dr Merry Gunawan
Dr Gary Reynolds
Dr Kile Green
et al. | Donor monocyte-derived macrophages promote human acute graft-versus-host disease | 2020 |
|
Professor Graham Jackson
| Excluding myeloma diagnosis using revised thresholds for serum free light chain ratios and M-protein levels | 2020 |
|
Dr Aneta Mikulasova
Professor Graham Jackson
| Microhomology-mediated end joining drives complex rearrangements and overexpression of MYC and PVT1 in multiple myeloma | 2020 |
|
Professor Graham Jackson
| Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients | 2020 |
|
Professor Graham Jackson
| Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with multiple myeloma receiving systemic anti-cancer therapy | 2020 |
|
Professor Graham Jackson
| Renal outcome in patients with newly diagnosed multiple myeloma: Results from the UK NCRI Myeloma XI trial | 2020 |
|
Professor Graham Jackson
| The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial | 2020 |
|
Professor Graham Jackson
| Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials | 2020 |
|
Professor Graham Jackson
| A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study | 2019 |
|
Professor Graham Jackson
| Erratum to: Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma (Nature Communications, (2018), 9, 1, (3707), 10.1038/s41467-018-04989-w) | 2019 |
|
Dr Nicola Sunter
Professor Graham Jackson
Professor James Allan
| Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology | 2019 |
|
Professor Graham Jackson
| Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial | 2019 |
|
Professor Graham Jackson
| Physicians, paraproteins and progress: Diagnosis and management of myeloma | 2019 |
|
Professor Graham Jackson
| Transcriptome-wide association study of multiple myeloma identifies candidate susceptibility genes | 2019 |
|
Dr Katherine Sturgess
Dr Rachel Dickinson
Professor Andrew Gennery
Professor Andrew Cant
Professor Graham Jackson
et al. | In vivo T-depleted reduced intensity transplantation for GATA2-related immune dysfunction. | 2018 |
|
Professor Graham Jackson
| A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis | 2018 |
|
Professor Graham Jackson
| Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials | 2018 |
|
Professor Graham Jackson
| Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma | 2018 |
|
Professor Graham Jackson
| Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma | 2018 |
|
Dr Urszula Cytlak-Chaudhuri
Dr Anastasia Resteu
Dr Tom Altmann
Professor Andrew Gennery
Professor Graham Jackson
et al. | Ikaros family zinc finger 1 regulates dendritic cell development and function in humans | 2018 |
|
Dr Sarah Fordham
Dr Helen Blair
Dr Claire Elstob
Professor Ruth Plummer
Dr Yvette Drew
et al. | Inhibition of ATR acutely sensitises acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase | 2018 |
|
Professor Graham Jackson
| Maintenance Treatment and Survival in Patients with Myeloma: A Systematic Review and Network Meta-Analysis | 2018 |
|
Professor Graham Jackson
| Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network | 2018 |
|
Professor Graham Jackson
| Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma: findings of the Medical Research Council Myeloma IX randomised study | 2018 |
|
Professor Graham Jackson
| Subclonal TP53 copy number is associated with prognosis in multiple myeloma | 2018 |
|
Professor Graham Jackson
| Active multiple myeloma suppresses and typically eliminates coexisting MGUS | 2017 |
|
Professor Graham Jackson
| Assessing the effect of obesity-related traits on multiple myeloma using a Mendelian randomisation approach | 2017 |
|
Professor Graham Jackson
| Diagnosis and monitoring for light chain only and oligosecretory myeloma using serum free light chain tests | 2017 |
|
Dr Nicola Sunter
Dr Andrew Hall
Dr Tryfonia Mainou-Fowler
Professor Graham Jackson
Dr Helen Marr
et al. | Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia | 2017 |
|
Dr Nicola Sunter
Professor Graham Jackson
Dr Thahira Rahman
Professor James Allan
| Genome-wide association analysis of chronic lymphocytic leukaemia, Hodgkin lymphoma and multiple myeloma identifies pleiotropic risk loci | 2017 |
|
Dr Kile Green
Dr Kim Pearce
Dr Laura Jardine
Dr Venetia Bigley
Professor Graham Jackson
et al. | Impact of Alemtuzumab Scheduling on Graft-versus-Host Disease after Unrelated Donor Fludarabine and Melphalan Allografts | 2017 |
|
Professor Graham Jackson
| Neutral tumor evolution in myeloma is associated with poor prognosis | 2017 |
|
Professor Graham Jackson
| Response comparison of multiple myeloma and monoclonal gammopathy of undetermined significance to the same anti-myeloma therapy: a retrospective cohort study | 2017 |
|
Professor Graham Jackson
Professor James Allan
| Telomere length is a critical determinant for survival in multiple myeloma | 2017 |
|
Dr Aneta Mikulasova
Professor Graham Jackson
| The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma | 2017 |
|
Professor Graham Jackson
| The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myeloma | 2017 |
|
Professor Graham Jackson
| Deletion of CDKN2C drives the prognostic impact of deletion 1P in multiple myeloma | 2016 |
|
Professor Graham Jackson
| DYNAMIC EVOLUTION OF COPY NUMBER ABERRATIONS ACCOMPANIES DISEASE RELAPSE IN MULTIPLE MYELOMA | 2016 |
|
Dr Gail Jones
Professor Graham Jackson
| Evolving concepts in tumour lysis syndrome management - response to Ayed et al | 2016 |
|
Professor Graham Jackson
| Genetic factors influencing the risk of multiple myeloma bone disease | 2016 |
|
Professor Graham Jackson
| Genome-wide association study identifies multiple susceptibility loci for multiple myeloma | 2016 |
|
Professor Graham Jackson
| Genome-wide association study identifies variation at 6q25.1 associated with survival in multiple myeloma | 2016 |
|
Dr Kim Pearce
Jean Norden
Professor Graham Jackson
Professor Anne Dickinson
| Impact of genomic risk factors on survival after haematopoietic stem cell transplantation for patients with acute leukaemia | 2016 |
|
Professor Graham Jackson
| Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen | 2016 |
|
Professor Graham Jackson
| Minimal residual disease predicts outcome in transplant ineligible myeloma patients: Results from the UK NCRI Myeloma XI trial | 2016 |
|
Professor Graham Jackson
| Patients in the MRC Myeloma XI trial receiving induction chemotherapy for newly diagnosed multiple myeloma containing dexamethasone at full or moderated dose have significantly reduced half-life of IgG | 2016 |
|
Ka Lee
Becky Swan
Dr Ian Cowell
Professor Graham Jackson
Professor Caroline Austin
et al. | Proteasomal inhibition potentiates drugs targeting DNA topoisomerase II | 2016 |
|
Professor Graham Jackson
| Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial | 2016 |
|
Professor Graham Jackson
Dr Richard Quinton
| Testosterone treatment is not associated with increased risk of adverse cardiovascular events: results from the Registry of Hypogonadism in Men (RHYME) | 2016 |
|
Professor Graham Jackson
| The NCRI Myeloma XI trial for newly diagnosed symptomatic multiple myeloma (NDMM); second primary malignancy (SPM) incidence when lenalidomide is used as an induction and maintenance treatment option | 2016 |
|
Professor Graham Jackson
| The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma | 2016 |
|
Dr Laura Jardine
Dr Venetia Bigley
Dr Kim Pearce
Dr Alison Dickinson
Professor Graham Jackson
et al. | A comparative study of reduced dose alemtuzumab in matched unrelated donor and related donor reduced intensity transplants | 2015 |
|
Professor Graham Jackson
| A molecular diagnostic approach able to detect the recurrent genetic prognostic factors typical of presenting myeloma | 2015 |
|
Professor Graham Jackson
| APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma | 2015 |
|
Professor Graham Jackson
| Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations | 2015 |
|
Dr Nicola Sunter
Dr Helen Marr
Dr Andrew Hall
Dr Tryfonia Mainou-Fowler
Professor Graham Jackson
et al. | Common variation at 12q24.13 (OAS3) influences chronic lymphocytic leukemia risk | 2015 |
|
Catriona Manville
Kayleigh Smith
Dr Zbyslaw Sondka
Holly Rance
Dr Ian Cowell
et al. | Genome-wide ChIP-seq analysis of human TOP2B occupancy in MCF7 breast cancer epithelial cells | 2015 |
|
Dr Gail Jones
Professor Graham Jackson
| Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology | 2015 |
|
Professor Graham Jackson
| Implementation of genome-wide complex trait analysis to quantify the heritability in multiple myeloma | 2015 |
|
Professor Graham Jackson
| Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction | 2015 |
|
Professor Graham Jackson
| Molecular Subgroups of Hyperdiploidy and Their Prognostic Relevance - an Analysis of 1,036 Myeloma Trial Patients | 2015 |
|
Professor Graham Jackson
| Molecular Subtyping and Risk Stratification for the Classification of Myeloma | 2015 |
|
Dr Aneta Mikulasova
Professor Graham Jackson
| Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma | 2015 |
|
Professor Graham Jackson
| Myeloma XI Trial for Newly Diagnosed Multiple Myeloma (NDMM); A Report of Second Primary Malignancy (SPM) Rates and the Importance of Review of Reported Cases | 2015 |
|
Dr Kim Pearce
Jean Norden
Professor Matthew Collin
Professor Graham Jackson
Dr Udo Holtick
et al. | Predicting survival using clinical risk score and non-HLA immunogenetics | 2015 |
|
Professor Graham Jackson
| Quadruplet Vs Sequential Triplet Induction Therapy Approaches to Maximise Response for Newly Diagnosed, Transplant Eligible, Myeloma Patients | 2015 |
|
Professor Graham Jackson
| Spatiotemporal Analysis of Intraclonal Heterogeneity in Multiple Myeloma: Unravelling the Impact of Treatment and the Propagating Capacity of Subclones Using Whole Exome Sequencing | 2015 |
|
Professor Graham Jackson
| Specific Identification of High Risk Disease Using Molecular Profiling By Mymap (Myeloma MLPA and translocation PCR) of 1,036 Cases | 2015 |
|
Professor Graham Jackson
| The British Society for Haematology: 'What have the Romans ever done for us?' | 2015 |
|
Professor Graham Jackson
| The Quadruplet Combination of Carfilzomib, Cyclophosphamide, Lenalidomide, and Dexamethasone is Safe and Well Tolerated as Induction Therapy for Newly Diagnosed, Transplant Eligible, Myeloma Patients | 2015 |
|
Professor Graham Jackson
| Time to redefine Myeloma | 2015 |
|
Dr Nicola Sunter
Dr Andrew Hall
Dr Tryfonia Mainou-Fowler
Professor Graham Jackson
Professor James Allan
et al. | A genome-wide association study identifies multiple susceptibility loci for chronic lymphocytic leukemia | 2014 |
|
Professor Graham Jackson
| A retrospective multi-centre study of the effects of allogeneic haematopoietic SCT on pulmonary function | 2014 |
|
Professor Graham Jackson
| Apobec Family Mutational Signatures Are Associated with Poor Prognosis Translocations in Multiple Myeloma | 2014 |
|
Professor Graham Jackson
| Autologous stem cell transplantation in severe treatment-resistant Crohn's disease: long-term follow-up of UK patients treated on compassionate basis | 2014 |
|
Professor Graham Jackson
| High Resolution Genome Wide DNA Methylation Analysis in a Large Trial Group Reveals a Novel Epigenetically Defined Subgroup of Myeloma Patients Characterized By Developmental Gene Hypermethylation | 2014 |
|
Professor Graham Jackson
| High Throughput Genetic Profiling Using a Robust All-Molecular Diagnostic Approach Is Feasible to Specifically Identify a High Risk Group of Myeloma Patients | 2014 |
|
Professor Graham Jackson
| Minimal Residual Disease: What Are the Minimum Requirements? Reply | 2014 |
|
Professor Graham Jackson
| Mutational Patterns and Copy Number Changes at Diagnosis Are a Powerful Tool to Predict Outcome: Result of the Sequencing Study of 463 Newly Diagnosed Myeloma Trial Patients | 2014 |
|
Professor Graham Jackson
| Optimising the use of plerixafor in stem cell mobilisation | 2014 |
|
Professor Graham Jackson
| Optimizing induction and pretransplant consolidation for myeloma: Results of Myeloma XI, a phase III trial comparing different IMiDs | 2014 |
|
Professor Graham Jackson
| Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results | 2014 |
|
Professor Graham Jackson
| Psychosocial supportive care services for haematopoietic stem cell transplant patients; a service evaluation of three UK transplant centres | 2014 |
|
Professor Graham Jackson
| Rapid, Robust and Accessible Molecular Profiling of Biologically and Clinically Relevant Copy Number Alterations in Multiple Myeloma from Small Amounts of Tumor DNA | 2014 |
|
Professor Graham Jackson
| Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome | 2014 |
|
Dr Laura Jardine
Dr Kile Green
Professor Graham Jackson
Professor Matthew Collin
| Synergy of Unrelated Donor and Full Intensity Conditioning Breaks the Control of Graft Versus Host Disease By Alemtuzumab | 2014 |
|
Professor Graham Jackson
Dr Venetia Bigley
Professor Matthew Collin
| T cell depleted reduced intensity transplantation is effective for patients with GATA2 mutation and severe infections or respiratory compromise | 2014 |
|
Professor Graham Jackson
| The Extent of Intra-Clonal Genetic Diversity within the Myeloma Clone Is a Predictive Biomarker of Progression and Outcome after Treatment | 2014 |
|
Professor Graham Jackson
| The Spectrum of Epigenetic Mutations in Myeloma and Their Clinical Impact | 2014 |
|
Professor Graham Jackson
| The UK and Ireland Perspective: European Post-Approval Safety Study (Pass) in Relapsed/Refractory Multiple Myeloma Patients Treated with Lenalidomide, Bortezomib, and Thalidomide | 2014 |
|
Professor Graham Jackson
| Biologically defined risk groups can be used to define the impact of thalidomide maintenance therapy in newly diagnosed multiple myeloma | 2013 |
|
Professor Graham Jackson
Professor Julie Irving
Professor James Allan
| Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk | 2013 |
|
Dr Kile Green
Dr Laura Jardine
Dr Kim Pearce
Dr Venetia Bigley
Professor Graham Jackson
et al. | Defining The Optimal Dose Of Alemtuzumab In Unrelated Donor Reduced Intensity Allografts: A UK Retrospective Study | 2013 |
|
Dr Christopher Bacon
Sarah Wilkinson
Dr Gavin Spickett
Dr Helen Lucraft
Professor Graham Jackson
et al. | Epstein-Barr virus-independent diffuse large B-cell lymphoma in DNA ligase 4 deficiency | 2013 |
|
Professor Graham Jackson
| Long-term Follow-up of MRC Myeloma IX Trial: Survival Outcomes with Bisphosphonate and Thalidomide Treatment | 2013 |
|
Professor Graham Jackson
| Management of cytomegalovirus infection in haemopoietic stem cell transplantation | 2013 |
|
Professor Graham Jackson
| Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study | 2013 |
|
Professor Graham Jackson
| Response and biological subtype of myeloma are independent prognostic factors and combine to define outcome after high-dose therapy | 2013 |
|
Professor Graham Jackson
| The CCND1 c.870G > A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma | 2013 |
|
Dr Sarah Fordham
Dr Victoria Forster
Professor Graham Jackson
Dr Simon Bomken
Professor James Allan
et al. | A functional variant in the core promoter of the CD95 cell death receptor gene predicts prognosis in acute promyelocytic leukemia | 2012 |
|
Professor Graham Jackson
| A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial | 2012 |
|
Professor Graham Jackson
| Allogeneic Stem Cell Transplantation for Myelofibrosis in 2012 | 2012 |
|
Professor Graham Jackson
Professor Christine Harrison FRCPath FMedSci
Professor Simon Bailey
| Burkitt's lymphoma | 2012 |
|
Professor Graham Jackson
| Common variation at 3p22.1 and 7p15.3 influences multiple myeloma risk | 2012 |
|
Professor Graham Jackson
| Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results | 2012 |
|
Professor Graham Jackson
| Diagnosis and management of chronic graft-versus-host disease | 2012 |
|
Professor Graham Jackson
| Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial | 2012 |
|
Dr Mario Abinun
Professor Graham Jackson
| Haematopoietic stem cell transplantation (HSCT) in severe autoimmune diseases: analysis of UK outcomes from the British Society of Blood and Marrow Transplantation (BSBMT) data registry 1997-2009 | 2012 |
|
Dr Catherine Stroud
Professor Matthew Collin
Professor Graham Jackson
Dr Terence Flood
Dr John Mansfield
et al. | Idiopathic colitis following haematopoietic stem cell transplantation for chronic granulomatous disease: Three cases at a national centre | 2012 |
|
Professor Graham Jackson
| Mobilized Peripheral Blood Stem Cells Compared with Bone Marrow as the Stem Cell Source for Unrelated Donor Allogeneic Transplantation with Reduced-Intensity Conditioning in Patients with Acute Myeloid Leukemia in Complete Remission: An Analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation | 2012 |
|
Dr Ian Cowell
Dr Zbyslaw Sondka
Kayleigh Smith
Ka Lee
Catriona Manville
et al. | Model for MLL translocations in therapy-related leukemia involving topoisomerase IIβ-mediated DNA strand breaks and gene proximity | 2012 |
|
Dr Kay Padget
Hannah Curtis
Dr Ian Cowell
Dr Zbyslaw Sondka
Dr Nick Morris
et al. | MRE11 facilitates the removal of human topoisomerase II complexes from genomic DNA | 2012 |
|
Professor Graham Jackson
| Organ-specific management and supportive care in chronic graft-versus-host disease | 2012 |
|
Dr Jonathan Lane
Professor Mary Slatter
Professor Sophie Hambleton
Dr Terence Flood
Professor Andrew Cant
et al. | Outcome of haematopoietic stem cell transplantation in patients with chronic granulomatous disease at a national centre | 2012 |
|
Dr Katherine Sturgess
Professor Mary Slatter
Dr Venetia Bigley
Dr Rachel Dickinson
Professor Muzlifah Haniffa
et al. | Reduced-intensity haematopoietic stem cell transplant rescues immune function and corrects pulmonary alveolar proteinosis in DCML deficiency/GATA 2 mutation | 2012 |
|
Professor Graham Jackson
| Sequential Immunomodulatory Drug (IMiD) and Proteosome Inhibitor Therapy Improves Response Rates in Newly Diagnosed Multiple Myeloma: Preliminary Results From the Myeloma XI Trial | 2012 |
|
Professor Graham Jackson
| The Impact of Thalidomide Maintenance Therapy Varies Dependent Upon Biological Risk Grouping | 2012 |
|
Professor Graham Jackson
| A Gene Expression-Based Predictor for Myeloma Patients at High Risk of Developing Bone Disease on Bisphosphonate Treatment | 2011 |
|
Michael Batey
Dr Yan Zhao
Dr Helen Maitland
Professor Hing Leung
Dr Andrew Hall
et al. | Comparative pre-clinical evaluation of receptor tyrosine kinase inhibitors for the treatment of multiple myeloma | 2011 |
|
Professor Graham Jackson
| Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation | 2011 |
|
Dr Venetia Bigley
Professor Muzlifah Haniffa
Dr Xiao Wang
Dr Rachel Dickinson
Dr Naomi McGovern
et al. | Dendritic cell, monocyte, B and NK lymphoid deficiency: a novel but potentially fatal haematological disorder curable with haematopoietic stem cell transplantation | 2011 |
|
Professor Graham Jackson
| Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial | 2011 |
|
Dr Faye Cooles
Professor Graham Jackson
Professor John Isaacs
| Epstein-Barr virus-driven lymphoproliferative disorder post-CAMPATH-1H (alemtuzumab) in refractory polymyositis | 2011 |
|
Professor Graham Jackson
| Heterogeneity in the Prognostic Significance of 12p Deletion and Chromosome 5 Amplification in Multiple Myeloma | 2011 |
|
Professor Graham Jackson
| Mapping of Chromosome 1p Deletions in Myeloma Identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as Being Genes in Regions Associated with Adverse Survival | 2011 |
|
Professor Graham Jackson
| MRC Myeloma IX, 6 Year Median Follow-up (FU) Highlights the Importance of Long-Term FU in Myeloma Clinical Trials and Differential Effects of Thalidomide in High- and Low-Risk Disease | 2011 |
|
Jean Norden
Professor Matthew Collin
Professor Graham Jackson
Professor Anne Dickinson
| Prognostic Significance of Interleukin-7 Receptor-alpha Gene Polymorphisms in Allogeneic Stem-Cell Transplantation: A Confirmatory Study | 2011 |
|
Dr Katherine Sturgess
Professor Mary Slatter
Dr Venetia Bigley
Professor Muzlifah Haniffa
Dr Xiao Wang
et al. | Reduced Intensity Hematopoietic Stem Cell Transplant Rescues Immune Function and Corrects Pulmonary Alveolar Proteinosis in DCML Deficiency/GATA 2 Mutation | 2011 |
|
Professor Graham Jackson
| Results of the Medical Research Council (MRC) Myeloma IX study: Effects of zoledronic acid (ZOL) on overall survival (OS) in patients with multiple myeloma (MM) | 2011 |
|
Professor Graham Jackson
| The Interaction of Response and FISH-Based Risk Stratification to Better Define Clinical Outcome in Myeloma | 2011 |
|
Dr Shaheda Ahmed
Dr Xiao Wang
Professor Graham Jackson
Professor Anne Dickinson
| The Involvement of Epithelial Fas in a Human Model of Graft Versus Host Disease | 2011 |
|
Professor Graham Jackson
| The role of in vivo T-cell depletion on reduced-intensity conditioning allogeneic stem cell transplantation from HLA-identical siblings in patients with follicular lymphoma | 2011 |
|
Dr Ebtesam El-Gezawy
Professor Graham Jackson
Professor Anne Dickinson
| A biomarker panel associated with acute and chronic graft-versus-host disease | 2010 |
|
Dr Nicola Sunter
Professor Graham Jackson
Dr Simon Bomken
Professor James Allan
| A Functional Polymorphism In the CD95 Cell Death Receptor Associated with Prognosis In Acute Promyelocytic Leukemia | 2010 |
|
Professor Graham Jackson
Dr Simon Bomken
Professor James Allan
| A Functional Polymorphism In the CD95 Cell Death Receptor Associated with Prognosis In Acute Promyelocytic Leukemia | 2010 |
|
Professor Graham Jackson
Dr Nicola Sunter
Dr Andrew Hall
Professor Julie Irving
Professor James Allan
et al. | A polymorphism in the 3' UTR of IRF4 linked to susceptibility and pathogenesis in chronic lymphocytic leukaemia and Hodgkin lymphoma has limited impact in multiple myeloma | 2010 |
|
Dr Wei Cope
Dr Laura Jardine
Dr Venetia Bigley
Sarah Pagan
Brie Turner
et al. | A retrospective study of alemtuzumab level, t-cell chimerism and graft-versus-host disease using intermediate dose alemtuzumab for matched related and matched unrelated reduced-intensity transplantation | 2010 |
|
Professor Graham Jackson
Professor Matthew Collin
Jean Norden
| Clinical and genetic risk assessment for overall survival in haematopoietic stem cell transplantation | 2010 |
|
Dr Nicola Sunter
Dr Andrew Hall
Dr Tryfonia Mainou-Fowler
Professor Graham Jackson
Professor James Allan
et al. | Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk | 2010 |
|
Dr Faye Cooles
Professor Graham Jackson
Professor John Isaacs
| EBV driven lymphoproliferative disease following alemtuzumab (CAMPATH-1H) in refractory polymyositis | 2010 |
|
Dr John Byrne
Professor Graham Jackson
| First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial | 2010 |
|
Professor Graham Jackson
| Optimising Bone Disease In Myeloma, Zoledronic Acid Plus Thalidomide Combinations Improves Survival and Bone Endpoints Results of the MRC Myeloma IX Trial | 2010 |
|
Professor Graham Jackson
| Thalidomide maintenance significantly improves progression free (PFS) but not overall survival (OS) of myeloma patients, with PFS benerts in favourable fish subgroups only: MRC myeloma IX results | 2010 |
|
Professor Graham Jackson
| Thalidomide Maintenance Significantly Improves Progression Free Survival (PFS) and Overall Survival (OS) of Myeloma Patients When Effective Relapse Treatments Are Used MRC Myeloma IX Results | 2010 |
|
Professor Stephen Proctor
Dr Anne Lennard
Professor Graham Jackson
Dr Jennifer Wilkinson
Dr Michal Sieniawski
et al. | The role of an all-oral chemotherapy containing lomustine (CCNU) in advanced,fs progressive Hodgkin lymphoma: a patient-friendly palliative option which can result in long-term disease control | 2010 |
|
Professor James Allan
Dr Nicola Sunter
Dr Andrew Hall
Dr Christopher Bacon
Jonathan Pointon
et al. | Variant IRF4/MUM1 associates with CD38 status and treatment-free survival in chronic lymphocytic leukaemia | 2010 |
|
Professor Graham Jackson
| Zoledronic acid (ZOL) prolongs time to first skeletal-related event (SRE) and survival versus clodronate in newly diagnosed multiple myeloma (MM): MRC myeloma IX trail results | 2010 |
|
Professor Graham Jackson
| Zoledronic acid (ZOL) significantly increases progression-free survival (FPS) versus clodronate and may improve response rates in newly diagnosed multiple myeloma (MM): MRC myeloma IX trail results | 2010 |
|
Professor Graham Jackson
| Zoledronic acid (ZOL) significantly reduces skeletal-related events (SRES) versus clodronate (CLO) in patients (PTS) with multiple myeloma (MM): Results of the medical research council (MRC) Myeloma IX Study | 2010 |
|
Dr Venetia Bigley
Sarah Pagan
Brie Turner
Professor Graham Jackson
Professor Anne Dickinson
et al. | A Retrospective Study of Alemtuzumab Level, T Cell Chimerism and Graft Versus Host Disease Using Intermediate Dose Alemtuzumab for Matched Related and Matched Unrelated Reduced Intensity Transplantation. | 2009 |
|
Professor Anne Dickinson
Dr Kim Pearce
Professor Graham Jackson
Professor Matthew Collin
Jean Norden
et al. | Clinical and Genetic Risk Assessment for Overall Survival in Haematopoietic Stem Cell Transplantation (HSCT) | 2009 |
|
Anna Kuzyk-Czucha
Professor Graham Jackson
| Donor HSP70-hom gene polymorphism contributes to the development of chronic GvHD after allogeneic hematopoietic stem cell transplantation | 2009 |
|
Professor Anne Dickinson
Professor Graham Jackson
| G to C transition at position-173 of MIF gene of the recipient is associated with reduced relapse rates after allogeneic stem cell transplantation | 2009 |
|
Professor Graham Jackson
| Mobilized Peripheral Blood Stem Cells (PBSC) Compared with Bone Marrow (BM) as the Stem Cell Source for Unrelated Donor Allogeneic Transplantation with Reduced Intensity Conditioning (RIC-alloSCT) in Patients with Acute Myeloid Leukemia (AML) in Complete Remission (CR): a Retrospective Analysis From the ALWP of EBMT | 2009 |
|
Dr Xiao Wang
Dr Udo Holtick
Professor Matthew Collin
Professor Graham Jackson
Professor Catharien Hilkens
et al. | Regulatory T-Cell Suppression of CD8+ T-Cell-Mediated Graft-Versus-Host Reaction Requires Their Presence During Priming | 2009 |
|
Professor Graham Jackson
| The Addition of Thalidomide to the Induction Treatment of Newly Presenting Myeloma Patients Increases the CR Rate Which Is Likely to Translate Into Improved PFS and OS | 2009 |
|
Professor Graham Jackson
| The Role of In Vivo T-Cell Depletion On Reduced Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation From HLA-Identical Siblings in Patients with Follicular Lymphoma: An European Blood and Marrow Transplantation Study | 2009 |
|
Dr Laura Jones
Dr Stephen Hodges
Dr Terence Flood
Dr Gavin Spickett
Professor Graham Jackson
et al. | Unrelated donor and HLA-identical sibling haematopoietic stem cell transplantation cure chronic granulomatous disease with good long-term outcome and growth | 2009 |
|
Jane Harrold
Jean Norden
Professor Graham Jackson
Professor Anne Dickinson
| IL13 +2044 (Arg130Gln) Associates with Acute and Chronic Graft-Versus-Host Disease Following Haematopoietic Stem Cell Transplantation | 2008 |
|
Professor James Allan
Dr Nicola Sunter
Dr Andrew Hall
Dr Tryfonia Mainou-Fowler
Professor Graham Jackson
et al. | A Common Genetic Variant in the 3'UTR of IRF4/MUM1 Associates with Risk of Disease and Poor Prognosis in Chronic Lymphocytic Leukaemia | 2008 |
|
Dr Nicola Sunter
Dr Andrew Hall
Dr Tryfonia Mainou-Fowler
Professor Graham Jackson
Professor James Allan
et al. | A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia | 2008 |
|
Dr Elaine Willmore
Dr sarah Johnson
Dr Tryfonia Mainou-Fowler
Professor Graham Jackson
Dr Celine Cano
et al. | DNA-dependent protein kinase is a therapeutic target and an indicator of poor prognosis in B-cell chronic lymphocytic leukemia | 2008 |
|
Dr Elaine Willmore
Dr sarah Johnson
Clark Crawford
Dr Tryfonia Mainou-Fowler
Professor Graham Jackson
et al. | DNA-Dependent Protein Kinase Is a Therapeutic Target in Poor Prognosis B-Cell Chronic Lymphocytic Leukemia | 2008 |
|
Professor Anne Dickinson
Professor Graham Jackson
| G to C transition at position -173 of MIF gene of the recipient is associated with improved outcome after allogeneic stem cell transplantation | 2008 |
|
Professor Graham Jackson
| Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping | 2008 |
|
Dr Terence Flood
Dr Gavin Spickett
Professor Graham Jackson
Professor Matthew Collin
Dr Mario Abinun
et al. | Haematopoeitic stem cell transplantation for chronic granulomatous disease - a single-centre experience | 2008 |
|
Michael Batey
Dr Helen Maitland
Professor Hing Leung
Dr Andrew Hall
Professor Graham Jackson
et al. | In vitro activity of the multi targeted receptor tyrosine kinase inhibitor sunitinib against multiple myeloma cell lines is not predictive of in vivo xenograft response | 2008 |
|
Professor Graham Jackson
| Maintenance Thalidomide May Improve Progression Free but Not Overall Survival; Results from the Myeloma IX Maintenance Randomisation | 2008 |
|
Professor Graham Jackson
Professor James Allan
| Polymorphic MLH1 and risk of cancer after methylating chemotherapy for Hodgkin lymphoma | 2008 |
|
Professor Graham Jackson
| Position statement on the use of bortezomib in multiple myeloma | 2008 |
|
Jane Harrold
Dr Elizabeth Leitch
Jean Norden
Dr Xiao Wang
Professor Graham Jackson
et al. | Role of interleukin-13 in predicting graft-versus-host disease; functional and genotyping studies | 2008 |
|
Dr Michal Sieniawski
Dr Tryfonia Mainou-Fowler
Dr Jennifer Wilkinson
Dr John Davison
Professor Graham Jackson
et al. | The effect of Diffuse Large B-Cell Lymphoma (DLBCL) treatment regimens on survival: a prospective cohort study [Poster] | 2008 |
|
Professor Anne Dickinson
Professor Graham Jackson
| The role of genetic variants of NOD2/CARD15, a receptor of the innate immune system, in GvHD and complications following related and unrelated donor haematopoietic stem cell transplantation | 2008 |
|
Professor Graham Jackson
| Defining complete response in multiple myeloma: Role of the serum free light chain assay and multiparameter flow cytometry | 2007 |
|
Professor Graham Jackson
| High loading dose AmBisome® is efficacious and well tolerated in the management of invasive fungal infection in hematology patients | 2007 |
|
Professor Graham Jackson
| Response by SFLC and marrow flow cytometry in MRC myeloma IX | 2007 |
|
Professor Graham Jackson
| Thalidomide maintenance following high-dose therapy in multiple myeloma: a UK myeloma forum phase 2 study | 2007 |
|
Dr Sara Brown
Professor Graham Jackson
Professor Nick Reynolds
Dr Clifford Lawrence
| Chronic cutaneous graft-versus-host disease associated with multiple cutaneous squamous cell carcinomas | 2006 |
|
Dr David Milligan
Professor Graham Jackson
Dr Archibold Hunter
Dr Roger Pearce
| De-escalation of the alemtuzumab dose prior to nonmyeloablative HLA-identical sibling transplantation: Crucial role of timing | 2006 |
|
Professor Anne Dickinson
Professor Graham Jackson
| NOD2/CARD15 mutations associate with transplant-related mortality and GvHD) in HLA-identical sibling transplants: Detailed analysis of single SNPs in 209 recipient/donor pairs | 2006 |
|
Professor Graham Jackson
| Phase III trial of oral ibandronate versus intravenous zoledronic acid in multiple myeloma: Study design | 2006 |
|
Professor Anne Dickinson
Professor Graham Jackson
| Prognostic significance of NOD2/CARD15 polymorphisms in allogeneic HSCT from unrelated donors | 2006 |
|
Dr Elaine Willmore
Professor Graham Jackson
Dr Tryfonia Mainou-Fowler
Professor Caroline Austin
Professor barbara Durkacz
et al. | Sensitisation of B-CLL cells to chlorambucil and fludarabine via inhibition of the DNA damage sensor proteins, DNA-PK and ATM | 2006 |
|
Dr Xiao Wang
Professor Matthew Collin
Professor Graham Jackson
Professor Anne Dickinson
| Skin Explant Model of Human Graft-Versus-Host Disease: Prediction of Clinical Outcome and Correlation with Biological Risk Factors | 2006 |
|
Dr Elaine Willmore
Dr Tryfonia Mainou-Fowler
Professor Graham Jackson
Professor barbara Durkacz
| Targeting DNA-PK and ATM increases sensitivity to chlorambucil and fludarabine in chemoresistant and p53-defective B-CLL cells | 2006 |
|
Dr Penelope Taylor
Dr Brian Angus
Professor Graham Jackson
Dr Helen Lucraft
Professor Stephen Proctor
et al. | The addition of oral idarubicin to a chlorambucil/dexamethasone combination has a significant impact on time to treatment failure but none on overall survival in patients with low grade non-Hodgkin's lymphoma: Results of the Scotland and Newcastle Lymphoma Group randomized NHL VIII trial | 2006 |
|
Professor Matthew Collin
Professor Graham Jackson
Dr Jennifer Cavet
Dr Peter Middleton
Professor Anne Dickinson
et al. | The fate of human Langerhans cells in hematopoietic stem cell transplantation | 2006 |
|
Dr Xiao Wang
Professor Graham Jackson
Professor Anne Dickinson
| An in vitro test of steroid responsiveness using a modified human skin explant model for graft-versus-host disease | 2005 |
|
Professor Graham Jackson
Beth Gibson
| An open-label study of high-dose liposomal amphotericin B (AmBisome (R)) in the treatment of proven and probable invasive fungal infections | 2005 |
|
Professor Graham Jackson
| Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies | 2005 |
|
Dr Trevor Booth
Dr Peter Middleton
Professor Graham Jackson
Dr Jennifer Cavet
Dr Xiao Wang
et al. | Human langerhans cells in transplantation: Recipient cells survive conditioning but donor cells predominate at day 100 | 2005 |
|
Professor Graham Jackson
Dr Jennifer Cavet
Dr Trevor Booth
Dr Peter Middleton
Dr Xiao Wang
et al. | Human Langerhans cells in transplantation: Recipient cells survive conditioning but donor cells predominate at day 100 | 2005 |
|
Dr Mark Velangi
Professor Graham Jackson
| Less than half of patients aged 65 years or under with myeloma proceed to transplantation: results of a two region population-based survey | 2005 |
|
Professor Graham Jackson
| Renal safety of ibandronate | 2005 |
|
Professor Graham Jackson
| Response to Goodman et al.: Amyloidosis, not myeloma | 2005 |
|
Professor Graham Jackson
| Safety and compliance of intravenous and oral dosing regimens | 2005 |
|
Professor Graham Jackson
| Safety issues influence choice | 2005 |
|
Professor Graham Jackson
Dr Jennifer Cavet
Professor Anne Dickinson
| The fate of human Langerhans cells in hematopoietic stem cell transplantation | 2005 |
|
Professor Graham Jackson
| The issue of renal safety of zoledronic acid from a nephrologist's point of view | 2005 |
|
Dr Elaine Willmore
Dr Nicola Sunter
Dr Michael Tilby
Professor Graham Jackson
Professor Caroline Austin
et al. | A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia | 2004 |
|
Dr Mark Velangi
Elizabeth Matheson
Dr Penelope Taylor
Professor Graham Jackson
Dr Andrew Hall
et al. | BRAF gene is not mutated in mismatch repair-proficient or -deficient plasma cell dyscrasias | 2004 |
|
Dr Mark Velangi
Elizabeth Matheson
Professor Graham Jackson
Dr Penelope Taylor
Dr Andrew Hall
et al. | DNA mismatch repair pathway defects in the pathogenesis and evolution of myeloma | 2004 |
|
Edward Leung
Dr Brian Shenton
Professor Graham Jackson
Professor Kate Gould
David Talbot
et al. | Dynamic EBV gene loads in renal, hepatic, and cardiothoracic transplant recipients as determined by real-time PCR light cycler | 2004 |
|
Professor Graham Jackson
| Newly diagnosed myeloma pateints are at risk of venous thrombotic events - High risk patients need to be identified and recieve thromboprophylaxis: The MRC experience | 2004 |
|
Professor Anne Dickinson
Professor Graham Jackson
| NOD2/CARD15 mutations associate with transplant related mortality and GvHD in HLA-identical sibling transplants: Detailed analysis of single SNPs in 211 recipient/donor pairs | 2004 |
|
Professor Graham Jackson
Dr Mark Velangi
| Only a minority of age eligible patients with myeloma undergo treatment with autologous transplantation. A population based study of the contributory factors. A combined survey on behalf of The Northern Ireland Regional Haematology Group (NIRHG) and The Newcastle Regional Haematology Group (NRHG) | 2004 |
|
Professor Graham Jackson
Dr Mark Velangi
| Only a minority of myeloma patients aged under 65 years receive high-dose therapy with autologous transplantation | 2004 |
|
Professor Graham Jackson
| Results of an open-label study of high-dose liposomal amphotericin B (AmBisome) in the treatment of confirmed fungal infections in high-risk patients | 2004 |
|
Professor Graham Jackson
| Use of fludarabine in the treatment of acute myeloid leukemia | 2004 |
|
Eileen Leung
Dr Brian Shenton
Katherine Green
Katherine Gould
Professor Graham Jackson
et al. | Changes in EBV gene load in renal transplant recipients | 2003 |
|
Dr Theresa Wardell
Professor Patrick Chinnery
Dr Gillian Borthwick
Professor Robert Taylor
Professor Graham Jackson
et al. | Changes in the human mitochondrial genome after treatment of malignant disease | 2003 |
|
Dr Theresa Wardell
Elizabeth Ferguson
Professor Patrick Chinnery
Dr Gillian Borthwick
Professor Robert Taylor
et al. | Changes in the human mitochondrial genome after treatment of malignant disease | 2003 |
|
Dr Peter Middleton
Professor Anne Dickinson
Mandy Jarvis
Dr Jennifer Cavet
Dr Hannah Cullup
et al. | Clinical and genotypic risk factors for GvHD are modulated by prophylaxis: A multicentre cohort study of HLA matched sib-allo BMT | 2003 |
|
Dr Mark Velangi
Professor Graham Jackson
Dr Penelope Taylor
Dr Andrew Hall
Professor Julie Irving
et al. | DNA mismatch repair pathway defects in the pathogenesis and evolution of myeloma | 2003 |
|
Professor Graham Jackson
| Human herpesvirus 6 encephalitis following flag chemotherapy | 2003 |
|
Dr Peter Middleton
Jean Norden
Dr Hannah Cullup
Dr Jennifer Cavet
Professor Graham Jackson
et al. | Oestrogen receptor α gene polymorphism associates with occurrence of graft-versus-host disease and reduced survival in HLA-matched sib-allo BMT | 2003 |
|
Dr Hannah Cullup
Professor Anne Dickinson
Dr Jennifer Cavet
Professor Graham Jackson
Dr Peter Middleton
et al. | Polymorphisms of interleukin-1α constitute independent risk factors for chronic graft-versus-host disease after allogeneic bone marrow transplantation | 2003 |
|
Professor Stephen Proctor
Professor Graham Jackson
Dr Anne Lennard
Dr Brian Angus
Dr Katrina Wood
et al. | Strategic approach to the management of Hodgkin's disease incorporating salvage therapy with high-dose ifosfamide, etoposide and epirubicin: a Northern Region Lymphoma Group study (UK) | 2003 |
|
Dr Gail Stark
Professor Anne Dickinson
Professor Graham Jackson
Dr Penelope Taylor
Professor Stephen Proctor
et al. | Tumour necrosis factor receptor type II 196M/R genotype correlates with circulating soluble receptor levels in normal subjects and with graft-versus-host disease after sibling allogeneic bone marrow transplantation | 2003 |
|
Professor Stephen Proctor
Dr Brian Angus
Professor Graham Jackson
Dr Anne Lennard
Dr Penelope Taylor
et al. | A population-based study of intensive multi-agent chemotherapy with or without autotransplant for the highest risk Hodgkin's disease patients identified by the Scotland and Newcastle Lymphoma Group (SNLG) prognostic index. A Scotland and Newcastle Lymphoma Group study (SNLG HD III) | 2002 |
|
Dr Mark Velangi
Dr Michael Reid
Dr Nicholas Bown
Professor Graham Jackson
Professor Stephen Proctor
et al. | Acute lymphoblastic leukaemia of the L3 subtype in adults in the Northern health region of England 1983-99 | 2002 |
|
Professor Graham Jackson
Dr Penelope Taylor
| Acute myeloid leukaemia - Optimising treatment in elderly patients | 2002 |
|
Dr Xiao Wang
Professor Graham Jackson
Professor Anne Dickinson
| Interleukin-10 modulation of alloreactivity and graft-versus-host reactions | 2002 |
|
Mandy Jarvis
Professor Anne Dickinson
Professor Graham Jackson
Dr Xiao Wang
| The detection of apoptosis in a human in vitro skin explant assay for graft versus host reactions | 2002 |
|
Eileen Leung
Dr Brian Shenton
Professor Graham Jackson
Professor Kate Gould
David Talbot
et al. | Use of real-time PCR to measure Epstein-Barr virus genomes in whole blood | 2002 |
|
Dr Peter Middleton
Dr Hannah Cullup
Professor Anne Dickinson
Jean Norden
Professor Graham Jackson
et al. | Vitamin D receptor gene polymorphism associates with graft-versus-host disease and survival in HLA-matched sibling allogeneic bone marrow transplantation | 2002 |
|
Professor Graham Jackson
| A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation | 2001 |
|
Professor Graham Jackson
Dr David Milligan
| Accelerated telomere shortening following allogeneic transplantation is independent of the cell source and occurs within the first year post transplant | 2001 |
|
Dr Hannah Cullup
Professor Anne Dickinson
Professor Graham Jackson
Dr Peter Middleton
| Donor interleukin 1 receptor antagonist genotype associated with acute graft-versus-host disease in human leucocyte antigen-matched sibling allogeneic transplants | 2001 |
|
Dr Nicholas Bown
Dr Michael Reid
Dr Peter Hamilton
Professor Graham Jackson
Dr Penelope Taylor
et al. | Erythroleukaemia in the north of England: a population based study | 2001 |
|
Professor Graham Jackson
Dr Xiao Wang
Professor Anne Dickinson
| Histological correlation between different centers using the skin explant model to predict graft-versus-host disease following bone marrow transplantation | 2001 |
|
Professor Anne Dickinson
Jean Norden
Dr Penelope Taylor
Professor Graham Jackson
Dr Peter Middleton
et al. | Interferon-gamma and interleukin-6 gene polymorphisms associate with graft-versus-host disease in HLA-matched sibling bone marrow transplantation | 2001 |
|
Professor Graham Jackson
Professor Stephen Proctor
| Massive haemolysis in a group A recipient of a group O peripheral blood stem cell allogeneic transplant | 2001 |
|
Dr Xiao Wang
Professor Anne Dickinson
Professor Graham Jackson
| Minor histocompatibility antigen specific CTLs and in situ skin graft versus host reactions | 2001 |
|
Professor Graham Jackson
Filippo Di Franco
David Talbot
| Outcome of PTLD in renal and liver allograft recipients | 2001 |
|
Dr Anne Lennard
Professor Graham Jackson
| Stem cell transplantation | 2001 |
|
Professor Julie Irving
Dr Penelope Taylor
Professor Graham Jackson
Dr Andrew Hall
| The presence of mismatch repair defects in plasma cell dyscrasias | 2001 |
|
Dr Sally Coulthard
Dr Christopher Howell
Lynne Minto
Dr Peter Middleton
Professor Graham Jackson
et al. | A comparison of molecular and enzyme-based assays for the detection of thiopurine methyltransferase mutations | 2000 |
|
Dr Brian Angus
Dr Fergus Jack
Professor Graham Jackson
Professor Stephen Proctor
Dr Penelope Taylor
et al. | Improved estimation of tumour burden leads to better prognostic discrimination in classical hodgkin's disease in adults | 2000 |
|
Dr Anne Lennard
Professor Graham Jackson
| Science, medicine, and the future - Stem cell transplantation | 2000 |
|
Dr Janet McComb
Dr Patrick Kesteven
Emerita Professor Sally Marshall
Professor Graham Jackson
| Endothelial dysfunction, disordered coagulation and fibrinolysis in patients with type 2 diabetes and microalbuminuria | 1999 |
|
Dr Xiao Wang
Kerry-Ann Oliver
Professor Anne Dickinson
Professor Graham Jackson
| Increased sensitivity of the cord blood alloresponse to cyclosporin | 1999 |
|
Dr Peter Middleton
Jean Norden
Dr Jennifer Cavet
Professor Graham Jackson
Professor Anne Dickinson
et al. | Interleukin-6 gene polymorphism associated with absence of severe graft-versus-host-disease in allogeneic BMT: A possible genetic protection factor. | 1999 |
|
Professor Anne Dickinson
Professor Graham Jackson
Dr Penelope Taylor
Professor Stephen Proctor
| Use of a skin explant model for predicting GVHD in HLA-matched bone marrow transplants - effect of GVHD prophylaxis | 1999 |
|
Dr Peter Middleton
Dr Penelope Taylor
Professor Graham Jackson
Professor Stephen Proctor
Professor Anne Dickinson
et al. | Cytokine gene polymorphisms associating with severe acute graft-versus-host disease in HLA-identical sibling transplants | 1998 |
|
Professor Graham Jackson
Dr Penelope Taylor
Dr Anne Lennard
Professor Anne Dickinson
Dr Peter Hamilton
et al. | Single centre experience of allogeneic bone marrow transplantation with GvHD prophylaxis based on cyclosporin alone: March 1983 June 1997 | 1998 |
|
Professor Graham Jackson
Dr Philip Taylor
Dr David Goff
Dr Anne Lennard
Dr Brian Angus
et al. | High dose ifosfamide in combination with etoposide and epirubicin in the treatment of relapsed/refactory Hodgkin's disease: A report on toxicity and efficacy. | 1997 |
|
Professor Graham Jackson
Dr Penelope Taylor
Dr Peter Hamilton
Professor Stephen Proctor
| The use of an all oral chemotherapy (idarubicin and etoposide) in the treatment of acute myeloid leukaemia in the elderly: a report of toxicity and efficacy | 1997 |
|
Dr Andrew Hall
Professor Graham Jackson
| Congenital deficiency of thiopurine methyltransferase as a cause of pancytopenia in patients treated with azathioprine | 1996 |
|
Professor Julie Irving
Professor Stephen Proctor
Professor Graham Jackson
| Basophilia, t(15;17) translocation and atypical AML | 1995 |
|
Professor Graham Jackson
Dr Anne Lennard
Dr Peter Hamilton
Professor Stephen Proctor
| Low frequency of myelodysplasia after autologous bone marrow transplantation | 1995 |
|
Professor Graham Jackson
Dr Penelope Taylor
Dr Anne Lennard
Professor Stephen Proctor
| Autologous bone marrow transplantation in acute lymphoblastic leukaemia | 1994 |
|
Professor Graham Jackson
Dr Anne Lennard
Dr Penelope Taylor
Dr Peter Carey
Dr Brian Angus
et al. | Autologous bone marrow transplantation in poor-risk high-grade non-Hodgkin's lymphoma in first complete remission | 1994 |
|
Professor Anne Dickinson
Dr Peter Hamilton
Dr Penelope Taylor
Professor Graham Jackson
Professor Stephen Proctor
et al. | Cytokine involvement in predicting clinical graft-versus-host disease in allogeneic bone marrow transplant recipients | 1994 |
|
Professor Anne Dickinson
Professor Graham Jackson
Professor Stephen Proctor
| Monoclonal anti-TNF-α suppresses graft vs host disease reactions in an in vitro human skin model | 1994 |
|
Professor Graham Jackson
Dr Anne Lennard
Dr Penelope Taylor
Professor Stephen Proctor
| Rapid onset of chronic granulocytic leukaemia after treatment for Hodgkin's disease | 1994 |
|
Dr Mark Levasseur
Professor Graham Jackson
Dr Jennifer Kernahan
Professor Stephen Proctor
Dr Peter Middleton
et al. | Relapse of acute lymphoblastic leukaemia 14 years after presentation: use of molecular techniques to confirm true re-emergence | 1994 |
|
Dr Penelope Taylor
Professor Graham Jackson
Dr Anne Lennard
Dr Helen Lucraft
Professor Stephen Proctor
et al. | Autologous transplantation in poor risk Hodgkin's disease using high dose melphalan/etoposide conditioning with non-cryopreserved marrow rescue | 1993 |
|
Dr Anne Lennard
Dr Penelope Taylor
Professor Graham Jackson
Professor Stephen Proctor
| Peripheral blood stem-cell transplantation versus non-cryopreserved autologous bone-marrow transplantation | 1993 |
|
Dr Peter Middleton
Dr Penelope Taylor
Dr Michael Reid
Professor Graham Jackson
Professor Stephen Proctor
et al. | Alpha interferon gene deletions in adults, children and infants with acute lymphoblastic leukemia | 1991 |
|
Dr Anne Lennard
Professor Graham Jackson
Dr Peter Carey
Dr Peter Middleton
Professor Stephen Proctor
et al. | Secondary acute lymphoblastic leukaemia with 4:11 translocation following treatment for Hodgkin's disease | 1991 |
|
Professor Graham Jackson
Dr Andrea Clarke
Dr Penelope Taylor
Professor Anne Dickinson
Professor Stephen Proctor
et al. | Supernatant cell counts from long-term bone marrow culture correlate with the speed of engraftment following autologous bone marrow transplantation | 1991 |
|
Dr Anne Lennard
Dr Peter Carey
Professor Graham Jackson
Professor Stephen Proctor
| An effective oral combination in advanced relapsed Hodgkin’s disease prednisolone, etoposide, chlorambucil and CCNU | 1990 |
|
Professor Graham Jackson
Dr Jonathan Wallis
Dr Anne Lennard
Professor Stephen Proctor
| Hydroxyurea-induced acute alveolitis in a Patient with chronic myeloid leukaemia | 1990 |
|
Professor Stephen Proctor
Professor Graham Jackson
| Recombinant interferon alfa-2B in refractory idiopathic immune thrombocytopenia: Response | 1990 |
|
Professor Stephen Proctor
Professor Graham Jackson
Dr Peter Carey
Dr Roger Finney
| Improvement of platelet counts in steroid-unresponsive idiopathic immune thrombocytopenic purpura after short-course therapy with recombinant alpha 2b interferon | 1989 |
|
Professor Graham Jackson
Dr Peter Carey
Professor Stephen Proctor
| Severe renal toxicity due to intermediate-dose methotrexate | 1989 |
|
Professor Stephen Proctor
Professor Graham Jackson
Dr Peter Carey
| Short-course alpha-interferon therapy in severe unresponsive immune thrombocytopenic purpura | 1988 |
|
